SAGE Therapeutics (SAGE) Misses Q2 EPS by 14c

August 3, 2021 6:40 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($1.83), $0.14 worse than the analyst estimate of ($1.69). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.01 million.

  • Announced positive topline data from pivotal WATERFALL Study of zuranolone in patients with MDD showing statistically significant and clinically meaningful reduction in depressive symptoms at Day 15, primary endpoint
  • Continued pipeline expansion and acceleration advancing all three brain health franchises, including first patient dosed in SAGE-718 PARADIGM Parkinson’s disease Study Part B and initiation of Phase 1 program for SAGE-689
  • Updated enrollment guidance for Phase 3 SKYLARK Study of zuranolone in women with PPD with topline data now expected mid-2022
  • Company announces REDWOOD and RAINFOREST Studies not expected to be required for a potential zuranolone NDA submission

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Earnings, ARK